Table 1.
Characteristics of the study group according to EVR
| Without EVR (N=19) |
With EVR (N=46) |
Significance | |
|---|---|---|---|
| ALT>50 (U/L) | 14 (73.7 %) | 27 (58.7 %) | NS |
| IL28 B genotype: | |||
| CT | 13 (68.4 %) | 21 (45.6 %) | NS |
| TT | 3 (15.8 %) | 5 (10.9 %) | NS |
| CC | 3 (15.8 %) | 20 (43.5 %) | P=0.046 |
| Women | 5 (26.3 %) | 11 (23.9 %) | NS |
| Age>40 years | 8 (42.1 %) | 9 (19.6 %) | NS |
| HIV/HCV | 5 (26.3 %) | 13 (28.3 %) | NS |
| G>=2 | 7 (36.8 %) | 11 (23.9 %) | NS |
| S>=2 | 15 (78.9 %) | 32 (69.6 %) | NS |
| HCV genotype: | |||
| 1 | 15 (78.9 %) | 39 (84.8) % | NS |
| 4 | 4 (21.1 %) | 7 (15.2 %) | NS |
| HCV viremia >6 × 105 (IU/mL) | 13 (68.4 %) | 27 (58.7 %) | NS |
| ALT (U/L) | 72.0 (50.0-91.0) | 53.5 (39.0-83.0) | NS |
| Age (years) | 36.0 (21.0-51.0) | 30.5 (22.0-37.0) | NS |
|
HCV wiremia (× 106 IU/mL) |
4.1 (0.6-8.9) | 1.6 (0.4-5.1) | NS |
| IFI27 | 28.2 (5.8-50.8) | 5.7 (2.4-24.2) | P=0.011 |
| SOCS3 | 3.1 (2.4-15.2) | 5.4 (1.7-10.9) | NS |
| MiR-122 | 2.0 (0.9-2.8) | 3.0 (1.2-4.1) | NS |
Data are presented as a percentage (%) or median and interquartile range: median (25 %-75 %)
EVR, early virological response
In liver biopsy: G, grade of inflammation and necrosis; S, stage of fibrosis; NS, not significant